Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to ...

June 18 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer ...

AstraZeneca’s lung cancer drug datopotamab deruxtecan, also called Dato-DXd, failed to show a significant benefit to overall survival when compared to standard chemotherapy drug docetaxel ...

Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.

(Reuters) -AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer ...

AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...

The stock fell as much as 5.6% to 119.98 pounds in early trade. The overall survival, or OS rates, in the TROPION-Lung01 trial "did not reach statistical significance", the company said in a ...

Truqap, the breast cancer drug which was on trial has failed to meet its main goal, the drug manufacturer AstraZeneca said on Tuesday. It said that its breast cancer drug, Truqap, in combination ...

AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...